ArticleJournal of the Chinese Medical Association : JCMA2023
Immunoprofile of adenosquamous carcinoma in gastric cancer.
Article in Journal of the Chinese Medical Association : JCMA, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 20 citations in OpenAlex.
- Successful non-surgical management of locally advanced gastric adenocarcinoma with squamous differentiation and programmed death-ligand 1 combined positive score 75: a case report.Journal of medical case reports · 2026Article
- Rare Gastroesophageal Tumor Subtypes: Clinicopathologic Characteristics, Molecular Alterations, and Therapeutic Implications.Cancers · 2026Review
- Ferroptosis as a novel targeted therapy in gynecological malignant tumors.Discover oncology · 2026Review
- Clinicopathological significance of deficient DNA mismatch repair and MLH1 promoter methylation in gastric adenosquamous carcinoma.Virchows Archiv : an international journal of pathology · 2025Article
- A case of successful pembrolizumab plus FP neoadjuvant chemotherapy for a tumor preoperatively diagnosed as gastric squamous cell carcinoma.Clinical journal of gastroenterology · 2025Article
- A challenge for treating patients with extensive-stage small cell lung cancers, particularly for those with liver metastases.Journal of the Chinese Medical Association : JCMA · 2025Article
- Long-term remission of microsatellite instability-high adenosquamous carcinoma in gastric antrum: a case report.Frontiers in oncology · 2025Article
- Survival benefit of perioperative chemoradiotherapy in patients with resectable primary gastric adenosquamous carcinoma: a population-based cohort study.Frontiers in oncology · 2025Article
- Neoadjuvant therapy and locally advanced cancer diseases.Journal of the Chinese Medical Association : JCMA · 2024Article
- Winners of the 2023 honor awards for excellence at the annual meeting of the Chinese Medical Association-Taipei: Part VI.Journal of the Chinese Medical Association : JCMA · 2024Article
- Analysis of clinicopathological characteristics and prognosis on primary gastric adenosquamous carcinoma.Scientific reports · 2024Article
- Understanding gastric adenosquamous cell carcinoma: Insights from immunoprofiling.Journal of the Chinese Medical Association : JCMA · 2023Article
Corrections and comments
- Commented on by
Authors and funding
11 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGastric adenosquamous carcinoma (GASC) is a rare subtype of gastric cancer. Research on GASC treatment is limited, and its outcome is usually poor. We investigated the clinical features, immunoprofile of GASC, and determined the optimal treatment modality for these patients.
methodsPatients with GASC from Taipei Veterans General Hospital were retrospectively reviewed. Clinical features and treatment outcomes were evaluated. Adequate samples were examined for surrogate biomarkers for immunotherapy by IHC staining.
resultsTotal 14 (0.35%) GASC patients were found among 4034 gastric cancer patients. The median tumor size was 6.8 cm in 10 patients with stage III GASC, and all these patients underwent radical gastrectomy followed by adjuvant therapy. The median progression-free survival (PFS) and overall survival (OS) were 6.0 and 11.5 months, respectively. Two patients with stage IV GASC received frontline immunotherapy. Their median PFS and OS were 9.0 and 12.5 months. In immunoprofiling, 25.0% (n = 3), 75.0% (n = 9), and 33.3% (n = 4) of the samples had deficient mismatch repair (dMMR) protein, combined positive score (CPS) of ≥1, and CPS of ≥10, respectively. The univariate analysis revealed that programmed death-ligand 1 ≥5% (HR: 0.12; 95% CI: 0.01-0.97; p = 0.047) was significant associated with superior OS. One stage IV patient with CPS ≥10 and dMMR proteins received nivolumab monotherapy as frontline treatment that resulted 14-month PFS.
conclusionPatients with GASC are more likely to yield positive results for CPS and dMMR. Biomarkers should be examined, and immunotherapy can be considered as frontline systemic treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.